Korean J Urol.  2013 Dec;54(12):816-823.

Priapism: Current Updates in Clinical Management

• Song PH
• Moon KH

Abstract

Priapism is a persistent penile erection that continues for hours beyond, or is unrelated to, sexual stimulation. Priapism requires a prompt evaluation and usually requires an emergency management. There are two types of priapism: 1) ischemic (veno-occlusive or low-flow), which is found in 95% of cases, and 2) nonischemic (arterial or high-flow). Stuttering (intermittent or recurrent) priapism is a recurrent form of ischemic priapism. To initiate appropriate management, the physician must decide whether the priapism is ischemic or nonischemic. In the management of an ischemic priapism, resolution should be achieved as promptly as possible. Initial treatment is therapeutic aspiration with or without irrigation of the corpora. If this fails, intracavernous injection of sympathomimetic agents is the next step. Surgical shunts should be performed in cases involving failure of nonsurgical treatment. The first management of a nonischemic priapism should be observation. Selective arterial embolization is recommended for the management of nonischemic priapism in cases that request treatment. The goal of management for stuttering priapism is prevention of future episodes. This article provides a review of recent clinical developments in the medical and surgical management of priapism and an investigation of scientific research activity in this rapidly developing field of study.

Keyword

Erectile dysfunction; Priapism; Surgery

MeSH Terms

Emergencies
Erectile Dysfunction
Male
Penile Erection
Priapism*
Stuttering
Sympathomimetics
Sympathomimetics

Figure

• 

  FIG. 1 Management algorithm for priapism.

Reference

1. Broderick GA, Kadioglu A, Bivalacqua TJ, Ghanem H, Nehra A, Shamloul R. Priapism: pathogenesis, epidemiology, and management. J Sex Med. 2010; 7(1 Pt 2):476–500.

2. Canguven O, Cetinel C, Horuz R, Tarhan F, Hamarat B, Goktas C. Transient distal penile corporoglanular shunt as an adjunct to aspiration and irrigation procedures in the treatment of early ischemic priapism. Korean J Urol. 2013; 54:394–398.

3. Kim JH, Choi HJ, Ryu KH, Jeong YS, Choi YS, Lee SW. High flow priapism developed after treatment of low flow priapism. Korean J Urol. 2005; 46:876–878.

4. Burnett AL, Bivalacqua TJ. Priapism: new concepts in medical and surgical management. Urol Clin North Am. 2011; 38:185–194.

5. Burnett AL, Bivalacqua TJ. Priapism: current principles and practice. Urol Clin North Am. 2007; 34:631–642.

6. Ralph DJ, Garaffa G, Muneer A, Freeman A, Rees R, Christopher AN, et al. The immediate insertion of a penile prosthesis for acute ischaemic priapism. Eur Urol. 2009; 56:1033–1038.

7. Chow K, Payne S. The pharmacological management of intermittent priapismic states. BJU Int. 2008; 102:1515–1521.

8. Kato GJ. Priapism in sickle-cell disease: a hematologist's perspective. J Sex Med. 2012; 9:70–78.

9. Keoghane SR, Sullivan ME, Miller MA. The aetiology, pathogenesis and management of priapism. BJU Int. 2002; 90:149–154.

10. Broderick GA. Priapism. In : Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh urology. 10th ed. Philadelphia: Saunders;2011. p. 749–769.

11. Montague DK, Jarow J, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, et al. American Urological Association guideline on the management of priapism. J Urol. 2003; 170(4 Pt 1):1318–1324.

12. LeRoy TJ, Broderick GA. Doppler blood flow analysis of erectile function: who, when, and how. Urol Clin North Am. 2011; 38:147–154.

13. Ciampalini S, Savoca G, Buttazzi L, Gattuccio I, Mucelli FP, Bertolotto M, et al. High-flow priapism: treatment and long-term follow-up. Urology. 2002; 59:110–113.

14. Ralph DJ, Borley NC, Allen C, Kirkham A, Freeman A, Minhas S, et al. The use of high-resolution magnetic resonance imaging in the management of patients presenting with priapism. BJU Int. 2010; 106:1714–1718.

15. Huang YC, Harraz AM, Shindel AW, Lue TF. Evaluation and management of priapism: 2009 update. Nat Rev Urol. 2009; 6:262–271.

16. Lowe FC, Jarow JP. Placebo-controlled study of oral terbutaline and pseudoephedrine in management of prostaglandin E1-induced prolonged erections. Urology. 1993; 42:51–53.

17. Burnett AL. Surgical management of ischemic priapism. J Sex Med. 2012; 9:114–120.

18. Kulmala RV, Tamella TL. Effects of priapism lasting 24 hours or longer caused by intracavernosal injection of vasoactive drugs. Int J Impot Res. 1995; 7:131–136.

19. Muneer A, Minhas S, Freeman A, Kumar P, Ralph DJ. Investigating the effects of high-dose phenylephrine in the management of prolonged ischaemic priapism. J Sex Med. 2008; 5:2152–2159.

20. Munarriz R, Wen CC, McAuley I, Goldstein I, Traish A, Kim N. Management of ischemic priapism with high-dose intracavernosal phenylephrine: from bench to bedside. J Sex Med. 2006; 3:918–922.

21. Morrison BF, Burnett AL. Priapism in hematological and coagulative disorders: an update. Nat Rev Urol. 2011; 8:223–230.

22. Winter CC. Cure of idiopathic priapism: new procedure for creating fistula between glans penis and corpora cavernosa. Urology. 1976; 8:389–391.

23. Ebbehoj J. A new operation for priapism. Scand J Plast Reconstr Surg. 1974; 8:241–242.

24. Brant WO, Garcia MM, Bella AJ, Chi T, Lue TF. T-shaped shunt and intracavernous tunneling for prolonged ischemic priapism. J Urol. 2009; 181:1699–1705.

25. Hanafy HM, Saad SM, El-Rifaie M, Al-Ghorab MM. Early arabian medicine: contribution to urology. Urology. 1976; 8:63–67.

26. Burnett AL, Pierorazio PM. Corporal "snake" maneuver: corporoglanular shunt surgical modification for ischemic priapism. J Sex Med. 2009; 6:1171–1176.

27. Quackels R. Treatment of a case of priapism by cavernospongious anastomosis. Acta Urol Belg. 1964; 32:5–13.

28. Sacher EC, Sayegh E, Frensilli F, Crum P, Akers R. Cavernospongiosum shunt in the treatment of priapism. J Urol. 1972; 108:97–100.

29. Grayhack JT, McCullough W, O'conor VJ Jr, Trippel O. Venous bypass to control priapism. Invest Urol. 1964; 1:509–513.

30. Barry JM. Priapism: treatment with corpus cavernosum to dorsal vein of penis shunts. J Urol. 1976; 116:754–756.

31. Sedigh O, Rolle L, Negro CL, Ceruti C, Timpano M, Galletto E, et al. Early insertion of inflatable prosthesis for intractable ischemic priapism: our experience and review of the literature. Int J Impot Res. 2011; 23:158–164.

32. Deveci S, Martin D, Parker M, Mulhall JP. Penile length alterations following penile prosthesis surgery. Eur Urol. 2007; 51:1128–1131.

33. Salem EA, El Aasser O. Management of ischemic priapism by penile prosthesis insertion: prevention of distal erosion. J Urol. 2010; 183:2300–2303.

34. Burnett AL. Against: no surgery for stuttering priapism. J Urol. 2009; 181:450–451.

35. Ralph DJ, Pescatori ES, Brindley GS, Pryor JP. Intracavernosal phenylephrine for recurrent priapism: self-administration by drug delivery implant. J Urol. 2001; 165:1632.

36. Carson CC. For: surgery for stuttering priapism. J Urol. 2009; 181:449–450.

37. Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, et al. Priapism. J Sex Med. 2004; 1:116–120.

38. Bertolotto M, Zappetti R, Pizzolato R, Liguori G. Color Doppler appearance of penile cavernosal-spongiosal communications in patients with high-flow priapism. Acta Radiol. 2008; 49:710–714.

39. Marotte JB, Brooks JD, Sze D, Kennedy WA 2nd. Juvenile posttraumatic high-flow priapism: current management dilemmas. J Pediatr Surg. 2005; 40:E25–E28.

40. Cakan M, Altu Gcaron U, Aldemir M. Is the combination of superselective transcatheter autologous clot embolization and duplex sonography-guided compression therapy useful treatment option for the patients with high-flow priapism? Int J Impot Res. 2006; 18:141–145.

41. Numan F, Cantasdemir M, Ozbayrak M, Sanli O, Kadioglu A, Hasanefendioglu A, et al. Posttraumatic nonischemic priapism treated with autologous blood clot embolization. J Sex Med. 2008; 5:173–179.

42. Takao T, Osuga K, Tsujimura A, Matsumiya K, Nonomura N, Okuyama A. Successful superselective arterial embolization for post-traumatic high-flow priapism. Int J Urol. 2007; 14:254–256.